Best-confirmed hematologic response to dasatinib
| . | No. patients (%) . | |||
|---|---|---|---|---|
| 6-mo follow-up . | 8-mo follow-up . | |||
| MBC-CML . | LBC-CML . | MBC-CML . | LBC-CML . | |
| No. of patients | 74 | 42 | 74 | 42 |
| Overall hematologic response | 39 (53) | 15 (36) | 39 (53) | 15 (36) |
| Major hematologic response | 24 (32) | 13 (31) | 25 (34) | 13 (31) |
| CHR | 18 (24) | 11 (26) | 19 (26) | 11 (26) |
| NEL | 6 (8) | 2 (5) | 6 (8) | 2 (5) |
| Minor hematologic response | 15 (20) | 2 (5) | 14 (19) | 2 (5) |
| . | No. patients (%) . | |||
|---|---|---|---|---|
| 6-mo follow-up . | 8-mo follow-up . | |||
| MBC-CML . | LBC-CML . | MBC-CML . | LBC-CML . | |
| No. of patients | 74 | 42 | 74 | 42 |
| Overall hematologic response | 39 (53) | 15 (36) | 39 (53) | 15 (36) |
| Major hematologic response | 24 (32) | 13 (31) | 25 (34) | 13 (31) |
| CHR | 18 (24) | 11 (26) | 19 (26) | 11 (26) |
| NEL | 6 (8) | 2 (5) | 6 (8) | 2 (5) |
| Minor hematologic response | 15 (20) | 2 (5) | 14 (19) | 2 (5) |
Confirmed hematologic responses had to be maintained for a minimum of 4 weeks.